Crescita Therapeutics Reports Q1 2026 Results and Pending Acquisition by ClinActiv
Crescita Therapeutics Inc., a Canadian commercial dermatology company, announced its financial results for the first quarter ended March 31, 2026. The company reported revenue of $5,637,000 CAD, representing a significant increase from $3,537,000 CAD in the same period last year. Gross profit also rose to $2,644,000 CAD, while Adjusted EBITDA improved markedly to $238,000 CAD compared to a loss in the previous year. Despite higher operating expenses, the net loss remained manageable at $1,160,000 CAD. CEO Serge Verreault attributed the growth to increased manufacturing volumes and revenue from recently acquired skincare assets. Concurrently, Crescita is progressing with its proposed acquisition by ClinActiv Holdings Inc. in an all-cash deal valued at $0.80 per share, a 74% premium over recent trading prices. The company has filed materials for a special shareholder meeting scheduled for May 14, 2026, to approve the arrangement. An interim court order has been obtained, and the transaction is expected to close in the second quarter of 2026, leading to the delisting of Crescita’s shares from the Toronto Stock Exchange.
Wire timeline
Crescita Therapeutics Reports Q1 2026 Results and Pending Acquisition by ClinActiv
Crescita Therapeutics Inc., a Canadian commercial dermatology company, announced its financial results for the first quarter ended March 31, 2026. The company reported revenue of $5,637,000 CAD, representing a significant increase from $3,537,000 CAD in the same period last year. Gross profit also rose to $2,644,000 CAD, while Adjusted EBITDA improved markedly to $238,000 CAD compared to a loss in the previous year. Despite higher operating expenses, the net loss remained manageable at $1,160,000 CAD. CEO Serge Verreault attributed the growth to increased manufacturing volumes and revenue from recently acquired skincare assets. Concurrently, Crescita is progressing with its proposed acquisition by ClinActiv Holdings Inc. in an all-cash deal valued at $0.80 per share, a 74% premium over recent trading prices. The company has filed materials for a special shareholder meeting scheduled for May 14, 2026, to approve the arrangement. An interim court order has been obtained, and the transaction is expected to close in the second quarter of 2026, leading to the delisting of Crescita’s shares from the Toronto Stock Exchange.
Montreal Gazette